{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:56:29Z","timestamp":1782831389761,"version":"3.54.5"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Major Science and Technology Projects of the Xinjiang Uygur Autonomous Region","award":["2022A03012-4"],"award-info":[{"award-number":["2022A03012-4"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>While the link between nonalcoholic fatty liver disease (NAFLD) and hypertension is well recognized, the potential protective effects of the widely used antihypertensive medication, spironolactone, on NAFLD risk remain unclear. This study aimed to evaluate the impact of spironolactone on the development of NAFLD in hypertensive patients, shedding light on its potential broader clinical benefits beyond blood pressure control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 7241 participants were included. Propensity score matching (1\u2005:\u20054 ratio) was employed to minimize confounding factors, creating balanced groups of spironolactone users and nonusers. Multivariate Cox regression analysis and Kaplan\u2013Meier survival analysis were used to evaluate the association between spironolactone use and NAFLD risk. Restricted cubic splines (RCS) were applied to assess the dose\u2013response relationship, and subgroup and sensitivity analyses were performed to validate the robustness of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, the study included 4110 participants (822 spironolactone users and 3288 nonusers). Spironolactone use was associated with a significantly lower risk of NAFLD, with a 16.3% reduction in risk compared with nonusers (hazard ratio: 0.821; 95% confidence interval: 0.714\u20130.944). The RCS analysis revealed that a cumulative spironolactone dose exceeding 635\u2005mg*months was associated with a significant reduction in NAFLD risk. Subgroup and sensitivity analyses confirmed the consistency of these findings across various patient characteristics and conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates a significant association between spironolactone use and a reduced risk of NAFLD in hypertensive patients, suggesting that it may have potential dual benefits in managing hypertension and protecting liver health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/meg.0000000000002986","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:00:24Z","timestamp":1747148424000},"page":"1010-1020","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The potential of spironolactone to mitigate the risk of nonalcoholic fatty liver disease in hypertensive populations: evidence from a cohort study"],"prefix":"10.1097","volume":"37","author":[{"given":"Di","family":"Shen","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiwei","family":"Song","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Hu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintian","family":"Cai","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Zhou","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hong","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfang","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Hypertension Research Laboratory, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"R1-20251128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement.","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20251128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20251128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","article-title":"Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.","volume":"18","author":"Tamaki","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"R4-20251128","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC.","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"key":"R5-20251128","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2021.06.045","article-title":"Maternal obesity increases the risk and severity of NAFLD in offspring.","volume":"75","author":"Hagstr\u00f6m","year":"2021","journal-title":"J Hepatol"},{"key":"R6-20251128","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.","volume":"75","author":"Golabi","year":"2021","journal-title":"J Hepatol"},{"key":"R7-20251128","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jhep.2021.06.034","article-title":"Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.","volume":"75","author":"Simon","year":"2021","journal-title":"J Hepatol"},{"key":"R8-20251128","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies.","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"R9-20251128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2020.02.028","article-title":"Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.","volume":"73","author":"Ampuero","year":"2020","journal-title":"J Hepatol"},{"key":"R10-20251128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.02.051","article-title":"Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011).","volume":"63","author":"Lee","year":"2015","journal-title":"J Hepatol"},{"key":"R11-20251128","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"key":"R12-20251128","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jhep.2021.01.019","article-title":"Hypertension in NAFLD: an uncontrolled burden.","volume":"74","author":"Kasper","year":"2021","journal-title":"J Hepatol"},{"key":"R13-20251128","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1161\/STROKEAHA.120.033133","article-title":"Greater adherence to secondary prevention medications improves survival after stroke or transient ischemic attack: a linked registry study.","volume":"52","author":"Dalli","year":"2021","journal-title":"Stroke"},{"key":"R14-20251128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jalz.2011.05.2414","article-title":"Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus.","volume":"8","author":"Johnson","year":"2012","journal-title":"Alzheimers Dement"},{"key":"R15-20251128","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/dom.12989","article-title":"Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.","volume":"19","author":"Polyzos","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R16-20251128","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/ejhf.1802","article-title":"Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.","volume":"22","author":"de Denus","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R17-20251128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ejhf.2455","article-title":"Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"R18-20251128","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"R19-20251128","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"R20-20251128","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ejhf.2031","article-title":"Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics. Letter regarding the article \u2018Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT\u2019.","volume":"23","author":"\u010culi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R21-20251128","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.3390\/jcm13133798","article-title":"Effects of combined low-dose spironolactone plus vitamin E versus vitamin E monotherapy on lipidomic profile in non-alcoholic fatty liver disease: a post hoc analysis of a randomized controlled trial.","volume":"13","author":"Semertzidis","year":"2024","journal-title":"J Clin Med"},{"key":"R22-20251128","doi-asserted-by":"crossref","first-page":"1451383","DOI":"10.3389\/fendo.2024.1451383","article-title":"Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study.","volume":"15","author":"Shen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R23-20251128","doi-asserted-by":"crossref","first-page":"1424207","DOI":"10.3389\/fendo.2024.1424207","article-title":"Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout.","volume":"15","author":"Song","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R24-20251128","doi-asserted-by":"crossref","first-page":"1373862","DOI":"10.3389\/fendo.2024.1373862","article-title":"Correlation between plasma aldosterone concentration and bone mineral density in middle-aged and elderly hypertensive patients: potential impact on osteoporosis and future fracture risk.","volume":"15","author":"Song","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R25-20251128","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1038\/s41598-024-54971-4","article-title":"Association of the trajectory of plasma aldosterone concentration with the risk of cardiovascular disease in patients with hypertension: a cohort study.","volume":"14","author":"Cai","year":"2024","journal-title":"Sci Rep"},{"key":"R26-20251128","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/00325481.2025.2460417","article-title":"Association of plasma aldosterone concentration with arterial stiffness progression in hypertensive patients: insights from a longitudinal analysis.","volume":"137","author":"Zhou","year":"2025","journal-title":"Postgrad Med"},{"key":"R27-20251128","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/DDDT.S466904","article-title":"Effectiveness of spironolactone in reducing osteoporosis and future fracture risk in middle-aged and elderly hypertensive patients.","volume":"18","author":"Song","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R28-20251128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","article-title":"Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study.","volume":"51","author":"Dasarathy","year":"2009","journal-title":"J Hepatol"},{"key":"R29-20251128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/1753-0407.12056","article-title":"Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.","volume":"5","author":"Gao","year":"2013","journal-title":"J Diabetes"},{"key":"R30-20251128","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/SLA.0000000000001797","article-title":"Potential pitfalls of reporting and bias in observational studies with propensity score analysis assessing a surgical procedure: a methodological systematic review.","volume":"265","author":"Lonjon","year":"2017","journal-title":"Ann Surg"},{"key":"R31-20251128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00273171.2011.540480","article-title":"A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R32-20251128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge.","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"key":"R33-20251128","doi-asserted-by":"crossref","first-page":"4930355","DOI":"10.1155\/2022\/4930355","article-title":"Dose-response associations of metabolic score for insulin resistance index with nonalcoholic fatty liver disease among a nonobese Chinese population: retrospective evidence from a population-based cohort study.","volume":"2022","author":"Cai","year":"2022","journal-title":"Dis Markers"},{"key":"R34-20251128","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.2147\/IJGM.S319759","article-title":"Application of a novel prediction model for predicting 2-year risk of non-alcoholic fatty liver disease in the non-obese population with normal blood lipid levels: a large prospective cohort study from China.","volume":"14","author":"Ji","year":"2021","journal-title":"Int J Gen Med"},{"key":"R35-20251128","doi-asserted-by":"crossref","first-page":"8852198","DOI":"10.1155\/2020\/8852198","article-title":"A nomogram model based on noninvasive bioindicators to predict 3-year risk of nonalcoholic fatty liver in nonobese mainland Chinese: a prospective cohort study.","volume":"2020","author":"Cai","year":"2020","journal-title":"Biomed Res Int"},{"key":"R36-20251128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13098-023-01254-z","article-title":"Liver indicators affecting the relationship between BMI and hypertension in type 2 diabetes: a mediation analysis.","volume":"16","author":"Yao","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"R37-20251128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1751-2980.12830","article-title":"Development of new drugs for the treatment of nonalcoholic steatohepatitis.","volume":"21","author":"Tang","year":"2020","journal-title":"J Dig Dis"},{"key":"R38-20251128","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/CIRCULATIONAHA.124.070039","article-title":"Relationship between renin, aldosterone, aldosterone-to-renin ratio and arterial stiffness and left ventricular mass index in young adults.","volume":"150","author":"Ananda","year":"2024","journal-title":"Circulation"},{"key":"R39-20251128","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes.","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"R40-20251128","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.01.009","article-title":"Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension.","volume":"60","author":"Sung","year":"2014","journal-title":"J Hepatol"},{"key":"R41-20251128","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/ca.22374","article-title":"A review of the anatomy and clinical significance of adrenal veins.","volume":"27","author":"Cesmebasi","year":"2014","journal-title":"Clin Anat"},{"key":"R42-20251128","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/DMSO.S408722","article-title":"Relationship between plasma aldosterone concentrations and non-alcoholic fatty liver disease diagnosis in patients with hypertension: a retrospective cohort study.","volume":"16","author":"Hu","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R43-20251128","doi-asserted-by":"crossref","first-page":"107680","DOI":"10.1016\/j.exer.2019.05.020","article-title":"The renin-angiotensin-aldosterone system and its therapeutic targets.","volume":"186","author":"Mirabito Colafella","year":"2019","journal-title":"Exp Eye Res"},{"key":"R44-20251128","first-page":"288","article-title":"CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis.","volume":"53","author":"Yang","year":"2000","journal-title":"Horm Res"},{"key":"R45-20251128","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/dmd.110.032870","article-title":"Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.","volume":"38","author":"Knights","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R46-20251128","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MEG.0000000000001678","article-title":"Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver.","volume":"32","author":"Sehgal","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R47-20251128","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function.","volume":"77","author":"Beldhuis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R48-20251128","doi-asserted-by":"crossref","first-page":"629176","DOI":"10.3389\/fmed.2021.629176","article-title":"Effect of spironolactone on COVID-19 in patients with underlying liver cirrhosis: a nationwide case-control study in South Korea.","volume":"8","author":"Jeon","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R49-20251128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone.","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R50-20251128","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","article-title":"Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.","volume":"151","author":"Wada","year":"2010","journal-title":"Endocrinology"},{"key":"R51-20251128","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1161\/CIRCULATIONAHA.116.024369","article-title":"NLRP3 inflammasome mediates aldosterone-induced vascular damage.","volume":"134","author":"Bruder-Nascimento","year":"2016","journal-title":"Circulation"},{"key":"R52-20251128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","article-title":"Friedman, spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis.","volume":"83","author":"Wei","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R53-20251128","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.gastro.2016.09.017","article-title":"Estall, estrogen signals through peroxisome proliferator-activated receptor-\u03b3 coactivator 1\u03b1 to reduce oxidative damage associated with diet-induced fatty liver disease.","volume":"152","author":"Besse-Patin","year":"2017","journal-title":"Gastroenterology"},{"key":"R54-20251128","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jhep.2015.07.037","article-title":"Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.","volume":"63","author":"Zhang","year":"2015","journal-title":"J Hepatol"},{"key":"R55-20251128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endrev\/bnae021","article-title":"Adiponectin and adiponectin receptors in atherosclerosis.","volume":"46","author":"Gianopoulos","year":"2025","journal-title":"Endocr Rev"},{"key":"R56-20251128","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1210\/jc.2009-0980","article-title":"Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men.","volume":"94","author":"Frederiksen","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R57-20251128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0190-9622(08)80535-X","article-title":"Spironolactone in dermatology.","volume":"26","author":"Cunliffe","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R58-20251128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFPEF and chronic kidney disease.","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"R59-20251128","doi-asserted-by":"crossref","first-page":"e009693","DOI":"10.1161\/CIRCHEARTFAILURE.121.009693","article-title":"Proteomic analysis of effects of spironolactone in heart failure with preserved ejection fraction.","volume":"15","author":"Javaheri","year":"2022","journal-title":"Circ Heart Fail"},{"key":"R60-20251128","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jhep.2014.11.025","article-title":"Roles of alcohol consumption in fatty liver: a longitudinal study.","volume":"62","author":"Moriya","year":"2015","journal-title":"J Hepatol"},{"key":"R61-20251128","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial.","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"R62-20251128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ejhf.2428","article-title":"Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients.","volume":"24","author":"Potter","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"R63-20251128","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/ejhf.1917","article-title":"Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis.","volume":"22","author":"Kalogeropoulos","year":"2020","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:00:37Z","timestamp":1764338437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002986","relation":{},"ISSN":["1473-5687"],"issn-type":[{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}